IFF’s Cleaner Portfolio Meets a Stickier Cost Cycle

A raised outlook and a near-high stock cannot hide the two old problems: Health is still soft, and the pricing catch-up now runs into 2027.

IFF · Earnings Call · 2026-11-04

IFF’s third quarter had the shape of a clean transformation story. Revenue came in just under $2 billion, up roughly 5% on a comparable currency-neutral basis, with every segment growing. EBITDA rose 6% to $403 million, margin expanded 20 basis points to 20.8%, and management raised the low end of its full-year sales and EBITDA ranges. The stock has already voted: it is up 10.7% over the last 90 trading days and sits within 7.4% of its Nov. 2 high of $94.63, even though it remains 44% below the 2018 peak. At 2.0x revenue, IFF is no longer priced like a broken specialty-chemicals roll-up.

Taste and Scent carry the quarter — and the multiple

The proof is in Taste and Scent. Taste sales rose 6% to $687 million and segment EBITDA 7% to $128 million; Scent sales rose 6% to $689 million and EBITDA 10% to $139 million. Management framed the quarter around commercial momentum rather than macro. “a lot of our growth is coming from the new wins. And the new wins are coming at the base or higher margins.” — J. Erik Fyrwald, CEO · 2026-11-04 The keyword profile reflects that: new wins is the company’s top keyword this quarter, and global key accounts sits right behind it. Neither is new — IFF has been talking about new wins and key-account penetration for several quarters — but the persistence matters. It is the difference between a cost-cutting story and a demand story. Gross margin has also recovered to 43.7%, up 6.4 percentage points year over year in the latest filed quarter.

The cost line is back, and the calendar slipped

The less comfortable part is that the old cost cycle has not gone away. higher costs is the third-ranked company keyword this quarter — a sharp return after input costs and raw materials dominated earlier 2026 calls. CFO Michael DeVeau was blunt about the source: “The largest increases we are seeing are related to higher oil derivatives, including the impact on energy and logistics. it is pretty broad based.” — Michael DeVeau, CFO · 2026-11-04 That is energy cost and freight, not a company-specific raw-material squeeze. And the pricing catch-up has been pushed out: Q4 net price to input costs is expected to be unfavorable, with the biggest gap in Q1 2027 and improvement through the year. On the prior May call, DeVeau had described inflation recovery as “a 12- to 18-month period” — Michael DeVeau, CFO · 2026-05-06. The mechanism is the same; the timeline now stretches deeper into 2027. The company’s pricing actions are real, but they lag — and the market is already capitalizing the margin recovery.

Health is the promise that keeps moving right

The quarter’s real negative is Health & Biosciences. Segment sales rose only 1% to $566 million, with mid-single-digit growth in Food Biosciences and Grain Processing offset by a decline in Health. Worse for the narrative, management no longer expects a second-half turn. Eric Fyrwald:

This is definitely a market situation. Consumers in The U. S. And Europe have reduced spending on dietary supplements. Due to the economic pressures that many of us are feeling.
J. Erik Fyrwald, CEO · 2026-11-04

That is a very different message from May, when he said: “we expect the first-half Health to be flattish and then return to growth in the second half, with acceleration into 2027” — Erik Fyrwald, CEO · 2026-05-06. The Health business has now missed that marker. Q4 profitability in H&B is guided to soften partly because Health is a higher-margin business, so the mix hurts. The company still calls it a market issue, not an execution issue, but the credibility clock is ticking.

Food Ingredients: from story to execution

The portfolio story is further along. The $4.3 billion Food Ingredients sale is on track to close by the end of the first half of 2027: “we remain on track to close the transaction by the end of the first half of 27” — J. Erik Fyrwald, CEO · 2026-11-04. Food Ingredients remains a top-10 company keyword, but the emphasis has shifted from “should we sell it?” to stranded costs, separation readiness and proceeds. Management reiterated the $100 million stranded-cost target, with two-thirds eliminated within 12 months, and completed the $500 million accelerated share repurchase. Net debt to credit-adjusted EBITDA was 2.75x at quarter-end, up modestly because of the buyback; the sale proceeds are meant to repay that. The balance sheet is still the constraint: effective net cash of -$5.1 billion and interest coverage of 3.4x leave little room for a second strategic detour.

What the tape is saying

The stock is behaving as if the RemainCo story is already de-risked. Free cash flow is improving — $251 million in the latest reported quarter, with a 12.8% FCF margin — and the $371 million nine-month figure was $245 million better than last year. But the earnings base is still depressed, which is why 69x net income is less useful than the direction of travel. The market is paying for Taste/Scent momentum and a cleaner portfolio. It is not yet paying for Health. The interesting tension is that almost nothing in this report is genuinely new. GLP-1 came up again, but IFF has been leaning into protein and fiber for over a year. New wins, global key accounts, pricing actions, stranded costs, Food Ingredients — all recurring. What changed is the admission that Health’s recovery is not a second-half 2026 event, and that cost recovery now runs through 2027. Those are the two lines that can turn a near-high stock into a show-me story.